Abstract
Many dopamine antagonists are proven acute migraine treatments. Genetic studies also imply that polymorphisms in dopamine genes (DRD2 receptors) in persons with migraine may create dopamine hypersensitivity. However, treatment is limited by the adverse event profiles of conventional neuroleptics including extrapyramidal symtoms, anticholinergic and antihistaminergic effects, hyperprolactinemia, and prolonged cardiac QT interval. Atypical neuroleptics cause less extrapyramial symptoms and some atypical neuroleptics, including olanzapine and quetiapine, may be beneficial as both acute and preventive migraine treatment. The combination of prochlorperazine, indomethacin, and caffeine is effective in the treatment of the acute migraine attack. The mechanism of action by which neuroleptics relieve headache is probably related to dopamine D2 receptor antagonist. Other actions via serotonin (5HT) receptor antagonists may also be important, particularly for migraine prevention. Additional studies to clarify the mechanism of action of neuroleptics in migraine could lead to new drugs and better management of migraine.
Keywords: Neuroleptics, dopamine antagonists, migraine, headache
Central Nervous System Agents in Medicinal Chemistry
Title: Neuroleptics and Migraine
Volume: 9 Issue: 1
Author(s): Petcharat Dusitanond and William B. Young
Affiliation:
Keywords: Neuroleptics, dopamine antagonists, migraine, headache
Abstract: Many dopamine antagonists are proven acute migraine treatments. Genetic studies also imply that polymorphisms in dopamine genes (DRD2 receptors) in persons with migraine may create dopamine hypersensitivity. However, treatment is limited by the adverse event profiles of conventional neuroleptics including extrapyramidal symtoms, anticholinergic and antihistaminergic effects, hyperprolactinemia, and prolonged cardiac QT interval. Atypical neuroleptics cause less extrapyramial symptoms and some atypical neuroleptics, including olanzapine and quetiapine, may be beneficial as both acute and preventive migraine treatment. The combination of prochlorperazine, indomethacin, and caffeine is effective in the treatment of the acute migraine attack. The mechanism of action by which neuroleptics relieve headache is probably related to dopamine D2 receptor antagonist. Other actions via serotonin (5HT) receptor antagonists may also be important, particularly for migraine prevention. Additional studies to clarify the mechanism of action of neuroleptics in migraine could lead to new drugs and better management of migraine.
Export Options
About this article
Cite this article as:
Dusitanond Petcharat and Young B. William, Neuroleptics and Migraine, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152409787601888
DOI https://dx.doi.org/10.2174/187152409787601888 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Pleiotropic Effects of Cytokines on Acute Myocardial Infarction: G-CSF as A Novel Therapy for Acute Myocardial Infarction
Current Pharmaceutical Design Chemistory of Fibrates
Current Chemical Biology Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets HIF Inhibitors: New Hope for Cancer Therapy
Letters in Drug Design & Discovery Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Current Drug Targets Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Role of microRNAs in Vascular Remodeling
Current Molecular Medicine The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Post-cardiac Arrest Syndrome in Children
Current Pediatric Reviews